To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502
to the European (EU) and American (US) Humira reference products, following a single
subcutaneous (SC) dose of 40 mg in healthy volunteers.